Acalabrutinib in Combination with ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Trial Identifier: ACE-CL-002
Start Date:August 2014
Primary Completion Date: July 2020
Study Completion Date: December 2025
Condition: CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

US, TN Hermitage, TN, US, 37076
US, TX Fort Worth, TX, US, 76104
US, OH Columbus, OH, US, 43210